Background: Treatment of castrationresistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities.
Alternative treatment strategies to cytotoxic therapy should be explored. There is evidence that the continuous administration of cyclooxygenase 2 (COX2) inhibitors and the immunomodulatory agents thalidomide or lenalidomide can result in longterm disease stabilization.
Case Report: A 70-year-old patient with castrationresistant metastatic prostate cancer was treated with a combination of lowdose dexamethasone, celecoxib and subsequently lenalidomide. The patient had longterm disease stabilization for 33 months and a very good performance status despite moderate side effects, i.e. moderate Cushing's syndrome and mild laboratory hematologic toxicity.
Conclusion: The addition of lenalidomide to low-dose dexamethasone and celecoxib resulted in an impressive longterm disease stabilization of CRPC in this patient, allowing him to lead an active life with a good quality of life.
Written by:
Marschner N, Zaiss M. Are you the author?
Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg i.Br., Germany.
Reference: Onkologie. 2012;35(5):279-82.
doi: 10.1159/000337403
PubMed Abstract
PMID: 22868509
UroToday.com Prostate Cancer Section
